Free Trial
ASX:TLX

Telix Pharmaceuticals (TLX) Stock Price, News & Analysis

Telix Pharmaceuticals logo

About Telix Pharmaceuticals Stock (ASX:TLX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
746,789 shs
Average Volume
N/A
Market Capitalization
A$9.14 billion
P/E Ratio
290.42
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TLX Stock News Headlines

Why Telix shares could rocket 60%+
When the levee breaks
The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.tc pixel
See More Headlines

TLX Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Telix Pharmaceuticals investors own include bluebird bio (BLUE), Atara Biotherapeutics (ATRA), Esperion Therapeutics (ESPR), Forte Biosciences (FBRX), Faraday Future Intelligent Electric (FFIE), Abbott Laboratories (ABT) and ADMA Biologics (ADMA).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:TLX
CIK
N/A
Fax
N/A
Employees
234
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
A$0.15
Trailing P/E Ratio
290.42
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
A$49.19 million
Net Margins
6.63%
Pretax Margin
N/A
Return on Equity
11.29%
Return on Assets
7.97%

Debt

Debt-to-Equity Ratio
5.48
Current Ratio
0.99
Quick Ratio
3.00

Sales & Book Value

Annual Sales
A$645.68 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
8.35
Book Value
A$1.21 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
334,680,000
Free Float
N/A
Market Cap
A$9.14 billion
Optionable
Not Optionable
Beta
2.40
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (ASX:TLX) was last updated on 8/26/2025 by MarketBeat.com Staff
From Our Partners